drugset / Trial / NCT02293551

A Study of Lispro Formulations in Healthy Participants

NCT02293551

Phase 1 Completed 54 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The purposes of this study are to determine: * Part A * How quickly your body absorbs, breaks down and gets rid of the different formulations of insulin lispro compared to insulin lispro alone formulation. * The safety of insulin lispro in different formulations and any side effects that might be associated with it. * Part B: * How much insulin lispro from different dose ranges is found in the bloodstream using a test insulin lispro formulation (selected from Part A). * The safety of insulin lispro in different formulations and any side effects that might be associated with it. Participants may only enroll in one part. The study is expected to last up to 10 weeks for each part.

Timeline

Start
2014-12
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Lispro Protein / enzyme biologic Subcutaneous

Indications

No indication recorded.